Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'atypical antipsychotic' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 344 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Bao, JQ; Potts, BD
      Quantitative determination of olanzapine in rat brain tissue by high-performance liquid chromatography with electrochemical detection

      JOURNAL OF CHROMATOGRAPHY B
    2. Monroy, X; Romero, G; Perez, MP; Farre, AJ; Guitart, X
      Decrease of adenylyl cyclase activity and expression by a sigma(1) receptor ligand and putative atypical antipsychotic

      NEUROREPORT
    3. Bernardo, M; Parellada, E; Lomena, F; Catafau, AM; Font, M; Gomez, JC; Lopez-Carrero, C; Gutierrez, F; Pavia, J; Salamero, M
      Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint [I-123]IBZM SPECT study

      PSYCHIATRY RESEARCH-NEUROIMAGING
    4. Gefvert, O; Lundberg, T; Wieselgren, IM; Bergstrom, M; Langstrom, B; Wiesel, FA; Lindstrom, L
      D-2 and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study

      EUROPEAN NEUROPSYCHOPHARMACOLOGY
    5. Sharma, T
      Quetiapine - efficacy in different domains

      EUROPEAN NEUROPSYCHOPHARMACOLOGY
    6. Kasper, S; Tauscher, J; Heiden, A
      Quetiapine: efficacy and tolerability in schizophrenia

      EUROPEAN NEUROPSYCHOPHARMACOLOGY
    7. Naber, D; Moritz, S; Lambert, M; Rajonk, F; Holzbach, R; Mass, R; Andresen, B; Frank, P; Rudiger, H; Reinhard, M; Burghard, A
      Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs

      SCHIZOPHRENIA RESEARCH
    8. Ganguli, R; Brar, JS; Ayrton, Z
      Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone

      SCHIZOPHRENIA RESEARCH
    9. Bubser, M; Backstrom, JR; Sanders-Bush, E; Roth, BL; Deutch, AY
      Distribution of serotonin 5-HT2A receptors in afferents of the rat striatum

      SYNAPSE
    10. Rodriguez, JJ; Garcia, DR; Nakabeppu, Y; Pickel, VM
      FosB in rat striatum: Normal regional distribution and enhanced expressionafter 6-month haloperidol administration

      SYNAPSE
    11. Koskinen, T; Sirvio, J
      Studies on the involvement of the dopaminergic system in the 5-HT2 agonist(DOI)-induced premature responding in a five-choice serial reaction time task

      BRAIN RESEARCH BULLETIN
    12. Esel, E; Basturk, M; Gonul, AS; Kula, M; Turan, MT; Yabanoglu, I; Sofuoglu, S
      Effects of olanzapine and haloperidol on serum prolactin levels in male schizophrenic patients

      PSYCHONEUROENDOCRINOLOGY
    13. Stutzmann, GE; Marek, GJ; Aghajanian, GK
      Adenosine preferentially suppresses serotonin(2a) receptor-enhanced excitatory postsynaptic currents in layer V neurons of the rat medial prefrontal cortex

      NEUROSCIENCE
    14. Bantick, RA; Deakin, JFW; Grasby, PM
      The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?

      JOURNAL OF PSYCHOPHARMACOLOGY
    15. Butterfield, MI; Becker, ME; Connor, KM; Sutherland, S; Churchill, LE; Davidson, JRT
      Olanzapine in the treatment of post-traumatic stress disorder: a pilot study

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    16. Mullen, J; Jibson, MD; Sweitzer, D
      A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: The Quetiapine Experience with Safety and Tolerability (QUEST) study

      CLINICAL THERAPEUTICS
    17. Wadenberg, MLG; Browning, JL; Young, KA; Hicks, PB
      Antagonism at 5-HT2A receptors potentiates the effect of haloperidol in a conditioned avoidance response task in rats

      PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
    18. Zefirova, ON; Zefirov, NS
      Physiologically active compounds interacting with serotonin (5-hydroxytryptamine) receptors

      USPEKHI KHIMII
    19. Wood, MD; Reavill, C; Trail, B; Wilson, A; Stean, T; Kennett, GA; Lightowler, S; Blackburn, TP; Thomas, D; Gager, TL; Riley, G; Holland, V; Bromidge, SM; Forbes, IT; Middlemiss, DN
      SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety

      NEUROPHARMACOLOGY
    20. Marcus, MM; Mathe, JM; Nomikos, GG; Svensson, TH
      Effects of competitive and non-competitive NMDA receptor antagonists on dopamine output in the shell and core subdivisions of the nucleus accumbens

      NEUROPHARMACOLOGY
    21. Aloyo, VJ; Dave, KD; Rahman, T; Harvey, JA
      Selective and divergent regulation of cortical 5-HT2A receptors in rabbit

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    22. Brun, P; Leonetti, M; Sotty, F; Steinberg, R; Soubrie, P; Renaud, B; Suaud-Chagny, MF
      Endogenous neurotensin down-regulates dopamine efflux in the nucleus accumbens as revealed by SR-142948A, a selective neurotensin receptor antagonist

      JOURNAL OF NEUROCHEMISTRY
    23. Anji, A; Hanley, NRS; Kumari, M; Hensler, JG
      The role of protein kinase C in the regulation of serotonin-2A receptor expression

      JOURNAL OF NEUROCHEMISTRY
    24. Ichikawa, J; Ishii, H; Bonaccorso, S; Fowler, WL; O'Laughlin, IA; Meltzer, HY
      5-HT2A and D-2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-inducedcortical dopamine release

      JOURNAL OF NEUROCHEMISTRY
    25. Rowley, M; Bristow, LJ; Hutson, PH
      Current and novel approaches to the drug treatment of schizophrenia

      JOURNAL OF MEDICINAL CHEMISTRY
    26. Warawa, EJ; Migler, BM; Ohnmacht, CJ; Needles, AL; Gatos, GC; McLaren, FM; Nelson, CL; Kirkland, KM
      Behavioral approach to nondyskinetic dopamine antagonists: Identification of seroquel

      JOURNAL OF MEDICINAL CHEMISTRY
    27. Rodriguez, JJ; Garcia, DR; Nakabeppu, Y; Pickel, VM
      Enhancement of laminar FosB expression in frontal cortex of rats receivinglong chronic clozapine administration

      EXPERIMENTAL NEUROLOGY
    28. Naidu, PS; Kulkarni, SK
      Reversal of neuroleptic-induced orofacial dyskinesia by 5-HT3 receptor antagonists

      EUROPEAN JOURNAL OF PHARMACOLOGY
    29. Bhana, N; Foster, RH; Olney, R; Plosker, GL
      Olanzapine - An updated review of its use in the management of schizophrenia

      DRUGS
    30. Ichikawa, J; Dai, J; Meltzer, HY
      DOI, a 5-HT2A/2C receptor agonist, attenuates clozapine-induced cortical dopamine release

      BRAIN RESEARCH
    31. Pehek, EA; McFarlane, HG; Maguschak, K; Price, B; Pluto, CP
      M100,907, a selective 5-HT2A antagonist, attenuates dopamine release in the rat medial prefrontal cortex

      BRAIN RESEARCH
    32. Perry, KW; Nisenbaum, LK; George, CA; Shannon, HE; Felder, CC; Bymaster, FP
      The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex

      BIOLOGICAL PSYCHIATRY
    33. Sumiyoshi, T; Matsui, M; Yamashita, I; Nohara, S; Kurachi, M; Uehara, T; Sumiyoshi, S; Sumiyoshi, C; Meltzer, HY
      The effect of tandospirone, a serotonin(1A) agonist, on memory function inschizophrenia

      BIOLOGICAL PSYCHIATRY
    34. Tollefson, GD; Birkett, MA; Kiesler, GM; Wood, AJ
      Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine

      BIOLOGICAL PSYCHIATRY
    35. Di Matteo, V; De Blasi, A; Di Giulio, C; Esposito, E
      Role of 5 HT2C receptors in the control of central dopamine function

      TRENDS IN PHARMACOLOGICAL SCIENCES
    36. Barnas, C; Quiner, S; Tauscher, J; Hilger, E; Willeit, M; Kufferle, B; Asenbaum, S; Brucke, T; Rao, ML; Kasper, S
      In vivo I-123 IBZM SPECT imaging of striatal dopamine 2 receptor occupancyin schizophrenic patients

      PSYCHOPHARMACOLOGY
    37. Hietala, J; Kuoppamaki, M; Majasuo, H; Palvimaki, EP; Laakso, A; Syvalahti, E
      Sertindole is a serotonin 5-HT2c inverse agonist and decreases agonist butnot antagonist binding to 5-HT2c receptors after chronic treatment

      PSYCHOPHARMACOLOGY
    38. Jones, HM; Travis, MJ; Mulligan, R; Bressan, RA; Visvikis, D; Gacinovic, S; Ell, PJ; Pilowsky, LS
      In vivo 5-HT2A receptor blockade by quetiapine - An R91150 single photon emission tomography study

      PSYCHOPHARMACOLOGY
    39. Geyer, MA; Krebs-Thomson, K; Braff, DL; Swerdlow, NR
      Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review

      PSYCHOPHARMACOLOGY
    40. van Waarde, A
      Measuring receptor occupancy with PET

      CURRENT PHARMACEUTICAL DESIGN
    41. Hale, A; Azorin, JM; Kasper, S; Maier, W; Syvalahti, E; Van der Burght, M; Sloth-Nielsen, M; Wehnert, A
      Sertindole is associated with a low level of extrapyramidal symptoms in schizophrenic patients: Results of a phase III trial

      INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
    42. Altamura, AC; Bobes, J; Owens, DC; Gerlach, J; Hellewell, JSE; Kasper, S; Naber, D; Tarrier, N; Van Os, J
      Schizophrenia: diagnosis and continuing treatment - principles of practicefrom the European expert panel on the contemporary treatment of schizophrenia

      INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
    43. Naber, D; Kasper, S
      The importance of treatment acceptability to patients

      INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
    44. Tarrier, N; Bobes, J
      The importance of psychosocial interventions and patient involvement in the treatment of schizophrenia

      INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
    45. Hellewell, JSE; Gerlach, JES
      Opportunities and challenges presented by the new generation antipsychotics

      INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
    46. Ruiu, S; Marchese, G; Saba, PL; Gessa, GL; Pani, L
      The 5-HT2 antagonist ritanserin blocks dopamine re-uptake in the rat frontal cortex

      MOLECULAR PSYCHIATRY
    47. Ishigooka, J; Murasaki, M; Miura, S
      Olanzapine optimal dose: Results of an open-label multicenter study in schizophrenic patients

      PSYCHIATRY AND CLINICAL NEUROSCIENCES
    48. Procyshyn, RM; Kennedy, NB
      Theoretical basis for loxapine augmentation in risperidone partial responders

      CLINICAL DRUG INVESTIGATION
    49. Edgell, ET; Andersen, SW; Johnstone, BM; Dulisse, B; Revicki, D; Breier, A
      Olanzapine versus risperidone - A prospective comparison of clinical and economic outcomes in schizophrenia

      PHARMACOECONOMICS
    50. Lieberman, JA; Golden, R; Stroup, S; McEvoy, J
      Drugs of the psychopharmacological revolution in clinical psychiatry

      PSYCHIATRIC SERVICES
    51. Spielewoy, C; Roubert, C; Hamon, M; Nosten-Bertrand, M; Betancur, C; Giros, B
      Behavioural disturbances associated with hyperdopaminergia in dopamine-transporter knockout mice

      BEHAVIOURAL PHARMACOLOGY
    52. Murphy, CA; Feldon, J
      Low-dose clozapine pretreatment partially prevents haloperidol-induced deficits in conditioned active avoidance

      BEHAVIOURAL PHARMACOLOGY
    53. Barrot, M; Marinelli, M; Abrous, DN; Rouge-Pont, F; Le Moal, M; Piazza, PV
      The dopaminergic hyper-responsiveness of the shell of the nucleus accumbens is hormone-dependent

      EUROPEAN JOURNAL OF NEUROSCIENCE
    54. Verhoeff, NPLG; Meyer, JH; Kecojevic, A; Hussey, D; Lewis, R; Tauscher, J; Zipursky, RB; Kapur, S
      A voxel-by-voxel analysis of [F-18]setoperone PET data shows no substantial serotonin 5-HT2A receptor changes in schizophrenia

      PSYCHIATRY RESEARCH-NEUROIMAGING
    55. Simon, VM; Parra, A; Minarro, J; Arenas, MC; Vinader-Caerols, C; Aguilar, MA
      Predicting how equipotent doses of chlorpromazine, haloperidol, sulpiride,raclopride and clozapine reduce locomotor activity in mice

      EUROPEAN NEUROPSYCHOPHARMACOLOGY
    56. Carriere, P; Bonhomme, D; Lemperiere, T
      Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group)

      EUROPEAN PSYCHIATRY
    57. Fink-Jensen, A
      Novel pharmacological approaches to the treatment of schizophrenia

      DANISH MEDICAL BULLETIN
    58. Shadach, E; Gaisler, I; Schiller, D; Weiner, I
      The latent inhibition model dissociates between clozapine, haloperidol, and ritanserin

      NEUROPSYCHOPHARMACOLOGY
    59. Ohashi, K; Hamamura, T; Lee, Y; Fujiwara, Y; Suzuki, H; Kuroda, S
      Clozapine- and olanzapine-induced Fos expression in the rat medial prefrontal cortex is mediated by beta-adrenoceptors

      NEUROPSYCHOPHARMACOLOGY
    60. Carboni, E; Rolando, MTP; Silvagni, A; Di Chiara, G
      Increase of dialysate dopamine in the bed nucleus of stria terminalis by clozapine and related neuroleptics

      NEUROPSYCHOPHARMACOLOGY
    61. De la Garza, R; Madras, BK
      [H-3]PNU-101958, a D-4 dopamine receptor probe, accumulates in prefrontal cortex and hippocampus of non-human primate brain

      SYNAPSE
    62. Aguilar, MA; Mari-Sanmillan, MI; Morant-Deusa, JJ; Minarro, J
      Different inhibition of conditioned avoidance response by clozapine and DAD-1 and D-2 antagonists in male mice

      BEHAVIORAL NEUROSCIENCE
    63. Rosenberg, PB; Rosse, RB; Schwartz, BL; Deutsch, SI
      Nefazodone in the adjunctive therapy of schizophrenia: An open-label exploratory study

      CLINICAL NEUROPHARMACOLOGY
    64. Zhukovskaya, NL; Neumaier, JF
      Clozapine downregulates 5-hydroxytryptamine(6) (5-HT6) and upregulates 5-HT7 receptors in HeLa cells

      NEUROSCIENCE LETTERS
    65. Tarazi, FI; Zhang, KH; Baldessarini, RJ
      Olanzapine, quetiapine, and risperidone: long-term effects on monoamine transporters in rat forebrain

      NEUROSCIENCE LETTERS
    66. Zamanillo, D; Andreu, F; Ovalle, S; Perez, MP; Romero, G; Farre, AJ; Guitart, X
      Up-regulation of sigma(1) receptor mRNA in rat brain by a putative atypical antipsychotic and sigma receptor ligand

      NEUROSCIENCE LETTERS
    67. Kusumi, I; Takahashi, Y; Suzuki, K; Kameda, K; Koyama, T
      Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D-2 and serotonin 5-HT2A receptors in the rat brain

      JOURNAL OF NEURAL TRANSMISSION
    68. Bogan, AM; Shellhorn, E; Brown, ES; Mcdanald, C; Suppes, T
      Switching outpatients between atypical antipsychotics

      PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
    69. Scruggs, JL; Patel, S; Bubser, M; Deutch, AY
      DOI-induced activation of the cortex: Dependence on 5-HT2A heteroceptors on thalamocortical glutamatergic neurons

      JOURNAL OF NEUROSCIENCE
    70. Meisenzahl, EM; Dresel, S; Frodl, T; Schmitt, GJE; Preuss, UW; Rossmuller, B; Tatsch, K; Mager, T; Hahn, K; Moller, HJ
      D-2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study

      JOURNAL OF PSYCHOPHARMACOLOGY
    71. Schuld, A; Kuhn, M; Haack, M; Kraus, T; Hinze-Selch, D; Lechner, C; Pollmacher, T
      A comparison of the effects of clozapine and olanzapine on the EEG in patients with schizophrenia

      PHARMACOPSYCHIATRY
    72. Tyler-McMahon, BM; Boules, M; Richelson, E
      Neurotensin: peptide for the next millennium

      REGULATORY PEPTIDES
    73. Svensson, TH
      Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs

      BRAIN RESEARCH REVIEWS
    74. Buscema, CA; Abbasi, QA; Barry, DJ; Lauve, TH
      An algorithm for the treatment of schizophrenia in the correctional setting: The Forensic Algorithm Project

      JOURNAL OF CLINICAL PSYCHIATRY
    75. Zahm, DS
      An integrative neuroanatomical perspective on some subcortical substrates of adaptive responding with emphasis on the nucleus accumbens

      NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
    76. Dossenbach, MRK; Beuzen, JN; Avnon, M; Belmaker, RH; Elizur, A; Mark, M; Munitz, H; Schneidman, M; Shoshani, D; Kratky, P; Grundy, SL; Tollefson, GD
      The effectiveness of olanzapine in treatment-refractory schizophrenia whenpatients are nonresponsive to or unable to tolerate clozapine

      CLINICAL THERAPEUTICS
    77. Tariot, PN; Salzman, C; Yeung, PP; Pultz, J; Rak, IW
      Long-term use of quetiapine in elderly patients with psychotic disorders

      CLINICAL THERAPEUTICS
    78. David, SR; Taylor, CC; Kinon, BJ; Breier, A
      The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia

      CLINICAL THERAPEUTICS
    79. Nasu, R; Matsuo, H; Takanaga, H; Ohtani, H; Sawada, Y
      Quantitative prediction of catalepsy induced by amoxapine, cinnarizine andcyclophosphamide in mice

      BIOPHARMACEUTICS & DRUG DISPOSITION
    80. Inoue, T; Izumi, T; Maki, Y; Muraki, I; Koyama, T
      Effect of the dopamine D-1/5 antagonist SCH 23390 on the acquisition of conditioned fear

      PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
    81. Robichaud, AJ; Largent, BL
      Recent advances in selective serotonin receptor modulation

      ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 35
    82. Pal, JK; Sarino, WA
      Effect of risperidone on prolactinoma growth in a psychotic woman

      PSYCHOSOMATIC MEDICINE
    83. Copolov, DL; Link, CGG; Kowalcyk, B
      A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia

      PSYCHOLOGICAL MEDICINE
    84. Anji, A; Kumari, M; Hanley, NRS; Bryan, GL; Hensler, JG
      Regulation of 5-HT2A receptor mRNA levels and binding sites in rat frontalcortex by the agonist DOI and the antagonist mianserin

      NEUROPHARMACOLOGY
    85. Moller, HJ
      Current assessment of new/atypical neuroleptics

      NERVENARZT
    86. Gilliland, SL; Alper, RH
      Characterization of dopaminergic compounds at hD(2short), hD(4.2) and hD(4.7) receptors in agonist-stimulated [S-35]GTP gamma S binding assays

      NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
    87. Okubo, Y; Suhara, T; Suzuki, K; Kobayashi, K; Inoue, O; Terasaki, O; Someya, Y; Sassa, T; Sudo, Y; Matsushima, E; Iyo, M; Tateno, Y; Toru, M
      Serotonin 5-HT2 receptors in schizophrenic patients studied by positron emission tomography

      LIFE SCIENCES
    88. Millan, MJ
      Improving the treatment of schizophrenia: Focus on serotonin (5-HT)(1A) receptors

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    89. Duncan, GE; Miyamoto, S; Leipzig, JN; Lieberman, JA
      Comparison of the effects of clozapine, risperidone, and olanzapine on ketamine-induced alterations in regional brain metabolism

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    90. Liu, W; Wu, CF; Liu, J; Huang, M; Xiao, K
      Differential effects of acute administration of haloperidol and clozapine on ethanol-induced ascorbic acid release in rat striatum

      EUROPEAN JOURNAL OF PHARMACOLOGY
    91. Doherty, MD; Pickel, VM
      Ultrastructural localization of the serotonin 2A receptor in dopaminergic neurons in the ventral tegmental area

      BRAIN RESEARCH
    92. Ichikawa, J; Meltzer, HY
      The effect of serotonin(1A) receptor agonism on antipsychotic drug-induceddopamine release in rat striatum and nucleus accumbens

      BRAIN RESEARCH
    93. Rollema, H; Lu, Y; Schmidt, AW; Sprouse, JS; Zorn, SH
      5-HT1A receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex

      BIOLOGICAL PSYCHIATRY
    94. Jarskog, LF; Mattioli, MA; Perkins, DO; Lieberman, JA
      First-episode psychosis in a managed care setting: Clinical management andresearch

      AMERICAN JOURNAL OF PSYCHIATRY
    95. Sirota, P; Mosheva, T; Shabtay, H; Giladi, N; Korczyn, AD
      Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia

      AMERICAN JOURNAL OF PSYCHIATRY
    96. Bigliani, V; Mulligan, RS; Acton, PD; Ohlsen, RI; Pike, VW; Ell, PJ; Gacinovic, S; Kerwin, RW; Pilowsky, LS
      Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [I-123]epidepride single photon emission tomography (SPET) study

      PSYCHOPHARMACOLOGY
    97. Coutureau, E; Gosselin, O; Di Scala, G
      Restoration of latent inhibition by olanzapine but not haloperidol in entorhinal cortex-lesioned rats

      PSYCHOPHARMACOLOGY
    98. Porter, JH; McCallum, SE; Varvel, SA; Vann, RE
      The discriminative stimulus properties of the atypical antipsychotic olanzapine in rats

      PSYCHOPHARMACOLOGY
    99. Tarazi, FI; Baldessarini, RJ
      Dopamine D-4 receptors: significance for molecular psychiatry at the millennium

      MOLECULAR PSYCHIATRY
    100. Homan, EJ; Tulp, MTM; Nilsson, JE; Wikstrom, HV; Grol, CJ
      C5-substituted derivatives of 5-OMe-BPAT: Synthesis and interactions with dopamine D-2 and serotonin 5-HT1A receptors

      BIOORGANIC & MEDICINAL CHEMISTRY


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 10/12/19 alle ore 15:19:26